Supplemental Digital Content 5 – Proposed guidelines for reporting studies on treatment for metastatic uveal melanoma based on our experience in extracting the data for the systematic review and meta-analysis:

- anatomical site clearly specified, “conjunctival” or “uveal”; more precisely “choroidal”, “ciliary body”, or “iris”; and not “ocular”
- survival analysis carried out by the Kaplan-Meier method
- median interval from diagnosis of metastases to initiation of treatment reported
- beginning of the survival period, e.g. initiation of treatment, diagnosis of the metastases
- censorings along with a at-risk table provided
- median, rather than mean survival reported, including the method by which it was obtained, e.g. arithmetically, actuarial method, Kaplan-Meier method
- survival rate reported at key time points, e.g. 1-year, 2-year, 3-year
- patient-level data provided through a data repository, including available prognostic factors, e.g. staging, performance status, liver function, genetic alterations.